Berlin, 21 October 2019
Accelero Bioanalytics GmbH (“Accelero”) signed an agreement with the gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”) to support the non-clinical development of an Adeno-associated virus (AAV) with its bioanalytical and regulatory expertise.
CombiGene is developing a breakthrough gene therapy with potential to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment.
Accelero will be responsible to develop and validate an appropriate quantitative PCR assay for the detection of the AAV-based drug product in a broad panel of biomaterials.
Another integral part of the agreement is the development and validation of suitable immunogenicity assays to detect an immune response against the drug product and its expressed transgene(s).
All services will be provided in full compliance to Good Laboratory Practice (GLP) regulations.
Please click hereto download the complete press release.